Effects of Dapagliflozin on Central Hemodynamics and Urine Albumin Excretion in Patients With Type 2 Diabetes.
A Study of the Effects of Dapagliflozin on Ambulatory Aortic Pressure, Arterial Stiffness and Urine Albumin Excretion in Patients With Type 2 Diabetes
Sponsor: Hellenic Society for Medical Education
Terminated
On February 2019 Astra-Zeneca Greece decided to stop the financial support of the study.
Other Diabetes Mellitus trials with similar outcome
This PHASE4 trial investigates Diabetes Mellitus and is currently terminated or withdrawn. Hellenic Society for Medical Education leads this study, which shows 7 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Jan 2020 — Jan 2021 [monthly]
Terminated PHASE4
Status: Recruiting → Terminated
-
Jul 2018 — Jan 2020 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
Jun 2018 — Jul 2018 [monthly]
Not Yet Recruiting PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE4
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hellenic Society for Medical Education
For direct contact, visit the study record on ClinicalTrials.gov .